Lv61
2610 积分 2022-08-08 加入
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
3小时前
求助中
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
4小时前
已完结
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2天前
已完结
Autoantibodies in systemic lupus erythematosus: From immunopathology to therapeutic target
4天前
已完结
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review
1个月前
已完结
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review
1个月前
已完结
Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial
1个月前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
1个月前
已完结
A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy
1个月前
已完结
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
3个月前
已完结
皖公网安备34019202002308
